ATTD 2022: Dexcom EVP Discusses New Portfolio, Research, Increasing The Market Of CGMs
Executive Summary
Chad Patterson, Dexcom’s executive vice president of global marketing and product management, talked to Medtech Insight about the premium continuous glucose monitor manufacturer’s plans for facing stiff competition over the coming years.
You may also be interested in...
JPM 2024: Dexcom Touts Strong Results, Speaks On New Stelo Glucose Sensor
The company has recorded impressive growth over the past year and issued strong guidance for the next. It has also announced plans for a new glucose monitor specifically targeting type II diabetics.
UPDATED: JPM 2023: Baxter, Medtronic Pursue Simplification As Path To Growth
The annual J.P. Morgan Healthcare Conference includes presentations from major medtech companies; Some use the conference as a platform for major announcements while some just take the opportunity to explain their 2023 outlook to investors. Here are some of the highlights from the presentations first day of the meeting.
Dexcom’s G7 Expands Globally After A Long Wait
Dexcom has expanded the availability of its G7 sensor to five new markets, including the UK and Germany. FDA approval in the US has been delayed by software changes.